Loading...
Loading...
Alexion Pharmaceuticals, Inc.
ALXN today announced that
researchers have presented data from an ongoing multinational Phase 2
study of asfotase alfa in infants and young children with
hypophosphatasia (HPP), an inherited, ultra-rare metabolic disorder that
in this patient population leads to progressive damage to multiple vital
organs, destruction and deformity of bones, and death. The
study met its primary endpoint: infants and young children with HPP
treated with asfotase alfa had significant improvement in skeletal
mineralization from baseline as assessed radiographically after 24 weeks
of treatment (p=0.001). This response was observed as early as 12 weeks
and improvement continued at 48 weeks. Ninety three percent of the
patients survived the first 48 weeks of treatment with 80% of patients
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in